Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report

Metaplastic breast carcinoma (MBC) is an aggressive subtype of breast cancer, accounting for <1%. The clinical outcome is unknown due to the lack of treatment options. Here, we present the case of a 58-year-old woman with advanced MBC, in which standard adjuvant chemotherapy was unsuccessful. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yang, Liu, Jie, Jiang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984491/
https://www.ncbi.nlm.nih.gov/pubmed/35399948
http://dx.doi.org/10.3389/fendo.2022.810747
_version_ 1784682201053396992
author Fu, Yang
Liu, Jie
Jiang, Yu
author_facet Fu, Yang
Liu, Jie
Jiang, Yu
author_sort Fu, Yang
collection PubMed
description Metaplastic breast carcinoma (MBC) is an aggressive subtype of breast cancer, accounting for <1%. The clinical outcome is unknown due to the lack of treatment options. Here, we present the case of a 58-year-old woman with advanced MBC, in which standard adjuvant chemotherapy was unsuccessful. In the second-line therapy, she received anti-angiogenic(anlotinib) therapy plus chemotherapy. Finally, she was subsequently treated with immunotherapy (toripalimab) combined anlotinib and achieved partial response (PR); thus, immunotherapy plus anti-angiogenic therapy might be a novel option for advanced MBC patients.
format Online
Article
Text
id pubmed-8984491
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89844912022-04-07 Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report Fu, Yang Liu, Jie Jiang, Yu Front Endocrinol (Lausanne) Endocrinology Metaplastic breast carcinoma (MBC) is an aggressive subtype of breast cancer, accounting for <1%. The clinical outcome is unknown due to the lack of treatment options. Here, we present the case of a 58-year-old woman with advanced MBC, in which standard adjuvant chemotherapy was unsuccessful. In the second-line therapy, she received anti-angiogenic(anlotinib) therapy plus chemotherapy. Finally, she was subsequently treated with immunotherapy (toripalimab) combined anlotinib and achieved partial response (PR); thus, immunotherapy plus anti-angiogenic therapy might be a novel option for advanced MBC patients. Frontiers Media S.A. 2022-03-23 /pmc/articles/PMC8984491/ /pubmed/35399948 http://dx.doi.org/10.3389/fendo.2022.810747 Text en Copyright © 2022 Fu, Liu and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Fu, Yang
Liu, Jie
Jiang, Yu
Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
title Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
title_full Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
title_fullStr Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
title_full_unstemmed Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
title_short Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
title_sort partial response after toripalimab plus anlotinib for advanced metaplastic breast carcinoma: a case report
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984491/
https://www.ncbi.nlm.nih.gov/pubmed/35399948
http://dx.doi.org/10.3389/fendo.2022.810747
work_keys_str_mv AT fuyang partialresponseaftertoripalimabplusanlotinibforadvancedmetaplasticbreastcarcinomaacasereport
AT liujie partialresponseaftertoripalimabplusanlotinibforadvancedmetaplasticbreastcarcinomaacasereport
AT jiangyu partialresponseaftertoripalimabplusanlotinibforadvancedmetaplasticbreastcarcinomaacasereport

Ejemplares similares